Currently out of the existing stock ratings of Swayampakula Ramakanth, 462 are a BUY (95.45%), 20 are a HOLD (4.13%), 2 are a SELL (0.41%).

Swayampakula Ramakanth

Work Performance Price Targets & Ratings Chart

Analyst Swayampakula Ramakanth, carries an average stock price target met ratio of 33.31% that have a potential upside of 48.58% achieved within 183 days. Previously, Swayampakula Ramakanth worked at HC WAINWRIGHT.

Swayampakula Ramakanth’s has documented 895 price targets and ratings displayed on 63 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on PGEN, Precigen at 15-Aug-2025.

Wall Street Analyst Swayampakula Ramakanth

Analyst best performing recommendations are on EKSO (EKSO BIONICS HOLDINGS).
The best stock recommendation documented was for EKSO (EKSO BIONICS HOLDINGS) at 5/6/2025. The price target of $4 was fulfilled within 27 days with a profit of $3.57 (830.23%) receiving and performance score of 307.49.

Average potential price target upside

of $355.5 (77.04%) on TCRT (ALAUNOS THERAPEUTICS).
of $43 (57.15%) on TARA (PROTARA THERAPEUTICS).
of $23.46 (58.81%) on PSTI (PLURISTEM).

EKSO Ekso Bionics Holdings PGEN Precigen TRIL Trillium Therapeutics VSTM Verastem BCAB Bioatla BCYC Bicycle Therapeutics Ltd CALA Calithera Biosciences CDXS Codexis HARP Harpoon Therapeutics HOOK Hookipa Pharma ITOS Iteos Therapeutics MDXG MiMedx Group OCGN Ocugen PLSE Pulse Biosciences DCTH Delcath Systems ECOR Electrocore LLC MDNA Medicenna Therapeutics Corp PSNL Personalis SURF Surface Oncology VOR Vor Biopharma XFOR X4 Pharmaceuticals CORT Corcept Therapeutics MDWD Mediwound Ltd ONCR Oncorus IMGN ImmunoGen AFMD Affimed NV ALXO Alx Oncology Holdings ASXC Asensus Surgical CELU Celularity EDAP EDAP TMS SA INAB In8bio IPA Immunoprecise Antibodies Ltd LPTX Leap Therapeutics RWLK Rewalk Robotics Ltd SRGA Surgalign Holdings VCEL Vericel Corp Ord ABSI Absci Corp AVGR Avinger IPHA Innate Pharma JANX Janux Therapeutics TCRT Alaunos Therapeutics ATEC Alphatec Holdings AVEO AVEO Pharmaceuticals CASI CASI Pharmaceuticals CLRB Cellectar Biosciences PSTI Pluristem QSI QuantumSi JNCE Jounce Therapeutics KIN Kindred Biosciences SESN Sesen Bio TARA Protara Therapeutics MESO Mesoblast Ltd VBLT Vascular Biogenics Ltd EVAX Evaxion Biotech AS RDHL Redhill Biopharma Ltd CELC Celcuity LLC NUVL Nuvalent PYXS Pyxis Oncology ELEV Elevation Oncology CLGN Collplant Biotechnologies Ltd DFFN Diffusion Pharmaceuticals DNTH Dianthus Therapeutics MDAI Spectral AI

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Swayampakula Ramakanth (HCWAINWRIGHT)

Buy

$0.86 (27.39%)

3 months 13 days ago
(06-May-2025)

2/9 (22.22%)

$3.57 (830.23%)

349

Please subscribe to see the analyst performance score

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Swayampakula Ramakanth is most bullish on?

Potential upside of $73.25 has been obtained for CORT (CORCEPT THERAPEUTICS)

Which stock is Swayampakula Ramakanth is most reserved on?

Potential downside of -$1.79 has been obtained for CELC (CELCUITY LLC)

What Year was the first public recommendation made by Swayampakula Ramakanth?

On 2015